The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | Research updates in WM from ASH 2023
Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, provides insights into pivotal research in the field of Waldenström’s macroglobulinemia (WM), which was shared at ASH 2023. Dr Castillo mentions a triplet drug combination being assessed in the BRAWM trial (NCT04624906), updated prognostic frameworks for WM stratification, and ongoing research in CAR T-cell therapy for WM. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Pharmacyclics, BeiGene, Cellectar, AstraZeneca, Mustang Bio, Kite, Loxo, Abbvie
Research Funding: Pharmacyclics, BeiGene, Cellectar, AstraZeneca, Loxo, Abbvie
